Answers are grounded in this paper and cite their sources.
Cohort study reveals residual disease persisting primarily on lower limbs in patients receiving risankizumab, highlighting the legs as an emerging difficult-to-treat area.
Historically, difficult-to-treat areas in psoriasis included face, scalp, folds, genitalia, nails, and palmoplantar region. Recent studies have found that lower limbs behave like a "new" difficult-to-treat area as they can be the only site of residual disease even in patients undergoing biologic therapies.
No takes yet. Share an insight, caveat, or question.
Bardazzi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: